Close
CDMO Safety Testing 2026
Novotech

Liveo Research Expands Pharma Packaging Business

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...
- Advertisement -

Switzerland-based Liveo Research Group, a manufacturer of high-performance barrier films used for blister packaging in the pharmaceutical industry, has announced a 20,000 ton capacity expansion to its existing coating capabilities in Boetzingen, Germany.

With this investment, Liveo will underpin its market position in high barrier products. Its three production-lines, based in Germany and Singapore, will enable Liveo Research to provide enhanced security of supply to its customers in the Pharmaceutical industry.

The high capacity new line will include proprietary coating technology that will allow Liveo Research to produce very high-quality products, extremely efficiently. Following expected commissioning in Q3 2021, the total capacity will reach over 50,000 tons.

The investment will also include a new building equipped to meet the pharmaceutical industryโ€™s highest hygiene standards. Liveo Research had already commissioned a new slitter in June, and the addition of two more slitters will provide even more flexibility to address customer needs and reduce lead times.

Andreas Pfefferle, head of Liveoโ€™s Pharma Packaging Innovations business unit, said, โ€œWe have been growing this market very successfully over the last couple of years in response to our valued customersโ€™ demand to get the very best balance of performance and cost. With supply levels already stretched to meet the global demand, this expansion is absolutely the right step to enable us to provide our customers with superior quality, excellent service and shorter lead times. It will be a key enabler to continue our growth story.โ€

Dr. Carsten Heldmann, CEO of Liveo Research, added, โ€œIโ€™m really excited about this important step as it will propel Liveo to the next level of growth and support our customers with an even higher security of supply, high quality and innovative products.โ€ Iโ€™m also grateful to our shareholder Lindsay Goldberg for supporting the project and the rapid decision-making process.โ€

Thomas Unger, Partner at Lindsay Goldberg Vogel and Chairman of Liveo Research, said: โ€œWhen we acquired Liveo Research in November 2019 we envisioned this investment as a key step in our strategy for the company to significantly grow the pharmaceutical business. Hence, we are delighted that we could enable Liveo Research to this major investmentโ€.

Liveo Research AG
Liveo Research is a global manufacturer of rigid packaging solutions with five locations worldwide. For over 50 years, its manufacturing and product innovation activities have focused on customer-focused solutions for the pharmaceutical, printing and label, security and credit card industries worldwide. The company employs around 1,100 people and generated annual sales of more than 350 million euros.

Latest stories

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...

AstraZeneca UK Investment Resumes with ยฃ300m Commitment

In a reversal of its earlier stance, AstraZeneca has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป